Clinical Trial Update: Prevention of Unexplained Recurrent Abortion by Enoxaparine [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating enoxaparin to prevent unexplained recurrent abortion has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pregnancy Loss

Drugs mentioned

• Enoxaparin (enoxaparin sodium)

Snippet

Sponsor: University Hospital, Brest | Conditions: Alive and Viable Births | Phase 3 | Status: TERMINATED